A Phase I Trial To Evaluate the Safety and Immunogenicity of the UBI HIV-1MN PND Peptide Immunogen, Given by IM Injection, in Combination With the UBI Microparticulate Monovalent HIV-1 MN Branched Peptide Given Orally, in HIV-1 Uninfected Volunteers.

This study has been completed.

Study NCT00000846 Information provided by National Institute of Allergy and Infectious Diseases (NIAID)

First Received: November 2, 1999 Last Updated: June 23, 2005 History of Changes

No Study Results Posted for this Study

Study Status:	This study has been completed.
Estimated Study Completion Date:	No date given
Estimated Primary Completion Date:	No date given